Becker's Healthcare December 16, 2024
Jakob Emerson

The prices for some GLP-1s have dropped significantly in recent years for individuals covered by Medicare and commercial insurance, according to a November report from HHS.

In 2024, the U.S. list prices for a one-month supply for most GLP-1s are stable or increasing, but after payer negotiations and rebates, net prices for many GLP-1s have decreased since 2022. Net prices for GLP-1s are between 24% and 73% lower than list prices, indicating that most insurers are paying less than the manufacturer’s list price.

“The future path of prices of drugs in this class will be affected by the number of...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Govt Agencies, HHS, Insurance, Patient / Consumer, Pharma / Biotech, Provider, Survey / Study, Trends
National Health Expenditures In 2023: Faster Growth As Insurance Coverage And Utilization Increased
Startup SiteOne Secures $100M to Forge Ahead With Novel Non-Opioid Pain Meds
Health care package winners and losers
A New Weight Loss Drug With No Side Effects? Yes…So Far
The AI Advantage: Reimagining the Future of Drug Development

Share This Article